BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 1584862 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 1584862\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06769048-5265@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:BI 1584862: Phase 2 readout est. (NCT06769048)
DESCRIPTION:BI 1584862\, phase 2\, Age-Related Macular Degeneration.\nStudy
 : A Study to Test Different Doses of BI 1584862 in People With a Distinct 
 Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy\n
 Estimated primary completion: 22 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bi-1584862#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06769048
URL:https://assetmemo.bio/drug/bi-1584862#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
